Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public Offering October 16, 2019
Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities October 1, 2019
Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant September 18, 2019
Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow August 9, 2019
Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS Caremark July 9, 2019
Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine® June 4, 2019
